Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80 molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
10730877
Knihovny.cz E-zdroje
- MeSH
- antigeny CD80 metabolismus MeSH
- histokompatibilita - antigeny třídy I metabolismus MeSH
- interleukin-2 biosyntéza genetika MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- nádorové buňky kultivované MeSH
- plazmocytom genetika imunologie terapie MeSH
- protinádorové vakcíny genetika imunologie účinky záření MeSH
- upregulace účinky záření MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigeny CD80 MeSH
- histokompatibilita - antigeny třídy I MeSH
- interleukin-2 MeSH
- protinádorové vakcíny MeSH
It has been found previously that irradiated, IL-2 gene-modified plasmacytoma (X63-m-IL-2) vaccines are more efficient in the therapy of the parental (X63-Ag8.653) plasmacytoma than live plasmacytoma vaccines. In this communication, we have demonstrated that irradiation of murine IL-2-producing plasmacytoma vaccines resulted in upregulation of CD80 molecule expression and IL-2 production. The expression of MHC class I antigens was not altered. The upregulation of the CD80 membrane molecule expression in X63-m-IL-2 cells was higher after irradiation with 150 Gy than after irradiation with 50 Gy. Comparable upregulation of the CD80 molecule expression has also been demonstrated after irradiation of the parental murine X63-Ag8.653 plasmacytoma cells. The results indicate that upregulation of the CD80 molecule expression and enhanced IL-2 production in irradiated X63-m-IL-2 cells was responsible for the higher therapeutic effectiveness of the irradiated plasmacytoma vaccine.
